Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Design Therapeutics ( (DSGN) ) has issued an update.
On May 18, 2026, Design Therapeutics reported new biomarker and clinical data from its ongoing Phase 1/2 RESTORE-FA trial of DT-216P2 in patients with Friedreich ataxia, in which 16 patients received weekly intravenous doses up to 1 mpk over four weeks. At the highest dose, patients showed mean improvements of 6.4 points on the modified Friedreich’s Ataxia Rating Scale and 2.7 points in Upright Stability Score, along with clinically meaningful reductions in fatigue sustained two weeks after treatment.
The company also reported dose-dependent increases in frataxin mRNA and protein in whole blood and affected muscle tissue, including a 65% rise in whole blood FXN mRNA and 42% in muscle FXN mRNA after four weeks at 1 mpk, reinforcing the mechanistic link between DT-216P2 and functional gains. DT-216P2 was generally well tolerated, with only mild to moderate adverse events such as transient ALT elevations, and based on these results Design Therapeutics plans to advance DT-216P2 on a registrational path, with a further development update expected in the fourth quarter of 2026.
The most recent analyst rating on (DSGN) stock is a Buy with a $21.00 price target. To see the full list of analyst forecasts on Design Therapeutics stock, see the DSGN Stock Forecast page.
Spark’s Take on DSGN Stock
According to Spark, TipRanks’ AI Analyst, DSGN is a Neutral.
The score is held back primarily by weak financial performance (no revenue, recurring losses, and negative free cash flow), which outweighs positives. Support comes from constructive technical momentum (price above major moving averages with positive MACD) and favorable recent corporate updates including stated multi-year cash runway and pipeline progress, while valuation remains challenging due to negative earnings and no provided dividend yield.
To see Spark’s full report on DSGN stock, click here.
More about Design Therapeutics
Design Therapeutics, Inc. operates in the biopharmaceutical industry, focusing on developing small-molecule therapies for genetic diseases. Its pipeline includes investigational treatments such as DT-216P2 for Friedreich ataxia, targeting disease-causing mechanisms with the aim of restoring normal cellular function in underserved patient populations.
Average Trading Volume: 397,233
Technical Sentiment Signal: Buy
Current Market Cap: $897.5M
For an in-depth examination of DSGN stock, go to TipRanks’ Overview page.